The following persons have been appointed to Bioretec's Shareholders' Nomination Board: Tor-Oskar Karlberg from Stephen Industries Inc Oy, Rami Vehmas from Keskinäinen Eläkevakuutusyhtiö Ilmarinen, and Heinz Moitzi from W&M GmbH.

The Nomination Board has elected Tor-Oskar Karlberg as its chairperson at its organizational meeting on September 16, 2025. The chairperson of the Board of Directors of Bioretec acts as an expert to the Nomination Board without voting rights.

In accordance with the decision taken by the 2024 Annual General Meeting, the Shareholders' Nomination Board consists of three members. Each of the three largest shareholders as of the last working day in August has the right to nominate a member.

The Shareholders' Nomination Board is responsible for preparing and presenting to the Annual General Meeting a proposal on the members of the Board of Directors as well as proposals on the remuneration and number of members of the Board of Directors. The Shareholders' Nomination Board will submit its proposals for the 2026 Annual General Meeting to the Board of Directors by 30 January 2026.

Further inquiries

Kustaa Poutiainen, Chairperson of the Board +358 40 042 4506

Certified advisor

Nordic Certified Adviser AB, +46 70 551 6729

Bioretec in brief

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.

Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA polymer. These implants deliver secure fixation through patented innovations and naturally degrade in approximately two years, eliminating the need for costly and invasive removal surgeries while supporting optimal bone regeneration. Activa products are both CE marked, and FDA cleared for a wide range of indications in adult and pediatric patients.

The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. With the development of next-generation implants like RemeOs, Bioretec is shaping the future of orthopedic treatment, paving the way for more effective and patient-friendly solutions.

To learn more about Bioretec, visit https://bioretec.com.Better healing - Better life. www.bioretec.com